<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2711234554
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BASAGLAR 100 u/ml solution for injection in Pre-Filled pen	
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        INSULIN GLARGINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        163.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ELI LILLY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ELI LILLY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ELI LILLY NEDERLAND B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10AE04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BASAGLAR contains insulin glargine. This is a modified insulin, very similar to human insulin.</p><p>BASAGLAR is used to treat diabetes mellitus in adults, adolescents and children aged 2&nbsp;years and above.</p><p>Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BASAGLAR</strong></p><p>If you are allergic to insulin glargine or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using BASAGLAR.</p><p>Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.</p><p>If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).</p><p><em>Skin changes at the injection site</em><u>.</u></p><p>The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work well if you inject into a lumpy area (See How to use Basaglar). Contact your doctor if you are currently injecting into a lumpy area before you start injecting into a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose.</p><p><em>Travel</em></p><p>Before travelling consult your doctor. You may need to talk about:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the availability of your insulin in the country you are visiting,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; supplies of insulin etc.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; correct storage of your insulin while travelling,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; timing of meals and insulin administration while travelling,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the possible effects of changing to different time zones,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; possible new health risks in the countries to be visited,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; what you should do in emergency situations when you feel unwell or become ill.</p><p><em>Illnesses and injuries</em></p><p>In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are not eating enough your blood sugar level may become too low (hypoglycaemia).</p><p>In most cases you will need a doctor. <strong>Make sure that you contact a doctor early.</strong></p><p>If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.</p><p>Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). However, only very rarely, this will require a change to your insulin dose.</p><p>Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p><em>Insulin mix-ups</em></p><p>You must always check the pack and insulin label before each injection to avoid mix-ups between BASAGLAR and other insulins.</p><p><strong>Children</strong></p><p>There is no experience with the use of BASAGLAR in children below the age of 2&nbsp;years.</p><p><strong>Other medicines and BASAGLAR</strong></p><p>Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine.</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.</p><p><em>Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:</em></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; all other medicines to treat diabetes,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disopyramide (used to treat certain heart conditions),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluoxetine (used to treat depression),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fibrates (used to lower high levels of blood lipids),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase (MAO) inhibitors (used to treat depression),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; make too much growth hormone),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulphonamide antibiotics.</p><p><em>Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:</em></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; corticosteroids (such as &quot;cortisone&quot; used to treat inflammation),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; danazol (medicine acting on ovulation),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diazoxide (used to treat high blood pressure),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diuretics (used to treat high blood pressure or excessive fluid retention),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glucagon (pancreas hormone used to treat severe hypoglycaemia),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; isoniazid (used to treat tuberculosis),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oestrogens and progestogens (such as in the contraceptive pill used for birth control),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenothiazine derivatives (used to treat psychiatric disorders),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; somatropin (growth hormone),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thyroid hormones (used to treat thyroid gland disorders),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; atypical antipsychotic medicines (such as clozapine, olanzapine),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; protease inhibitors (used to treat HIV)</p><p><em>Your blood sugar level may either rise or fall if you take:</em></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blockers (used to treat high blood pressure),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clonidine (used to treat high blood pressure),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium salts (used to treat psychiatric disorders).</p><p>Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.</p><p>Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia</p><p>If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.</p><p><strong>BASAGLAR with alcohol</strong></p><p>Your blood sugar levels may either rise or fall if you drink alcohol.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby.</p><p>If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.</p><p><strong>Driving and using machines</strong></p><p>Your ability to concentrate or react may be reduced if:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have hypoglycaemia (low blood sugar levels),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have hyperglycaemia (high blood sugar levels),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems with your sight.</p><p>Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). You should contact your doctor for advice on driving if:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have frequent episodes of hypoglycaemia,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.</p><p><strong>BASAGLAR&nbsp;contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, which means it is essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Although BASAGLAR contains the same active substance as Toujeo (insulin glargine 300&nbsp;units/mL), these medicines are not interchangeable. The switch from one insulin therapy to another requires medical prescription, medical supervision and blood glucose monitoring. Please consult your doctor for further information.</p><p><strong>Dose</strong></p><p>Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; determine how much BASAGLAR per day you will need and at what time,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell you when to check your blood sugar level, and whether you need to carry out urine tests,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell you when you may need to inject a higher or lower dose of BASAGLAR.</p><p>BASAGLAR is a long-acting insulin. Your doctor may tell you to use it in combination with a short-acting insulin or with tablets used to treat high blood sugar levels.</p><p>Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.</p><p><strong>Use in children and adolescents</strong></p><p><strong>&nbsp;</strong>BASAGLAR can be used in adolescents and children aged 2&nbsp;years and above. Use this medicine exactly as your doctor has told you.</p><p><strong>Frequency of administration</strong></p><p>You need one injection of BASAGLAR every day, at the same time of the day.</p><p><strong>Method of administration</strong></p><p>BASAGLAR is injected under the skin. Do NOT inject BASAGLAR in a vein, since this will change its action and may cause hypoglycaemia.</p><p>Your doctor will show you in which area of the skin you should inject BASAGLAR. With each injection, change the puncture site within the particular area of skin that you are using.</p><p>Basaglar is administered subcutaneously by injection in the abdominal wall, the thigh, the upper arm, the deltoid region or the gluteal region. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis.</p><p><strong>How to handle BASAGLAR KwikPen</strong></p><p>BASAGLAR KwikPen is a pre-filled disposable pen containing insulin glargine.</p><p><strong>Read carefully the &quot;</strong><strong>BASAGLAR KwikPen Instructions for Use&quot; included with this package leaflet. You must use the pen as described in these Instructions for Use.</strong></p><p>A new needle must be attached before each use. Only use needles that are compatible for use with BASAGLAR KwikPen (see &ldquo;BASAGLAR KwikPen Instructions for Use&rdquo;).</p><p>A safety test must be performed before each injection.</p><p>Look at the cartridge before you use the pen. Do not use BASAGLAR KwikPen if you notice particles in it. Only use BASAGLAR KwikPen if the solution is clear, colourless and water-like. Do not shake or mix it before use.</p><p>To prevent the possible transmission of disease, each pen must be used by one patient only.</p><p>Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.</p><p>Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. If you think you may have a problem with BASAGLAR KwikPen, consult your doctor, pharmacist or nurse.</p><p>Empty pens must not be re-filled and must be properly discarded.</p><p>Do not use BASAGLAR KwikPen if it is damaged or not working properly, it has to be discarded and a new KwikPen has to be used.</p><p>Perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</p><p><strong>If you use more BASAGLAR than you should</strong></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you <strong>have injected too much BASAGLAR&nbsp;</strong>or are unsure how much you have injected, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.</p><p><strong>If you forget to use BASAGLAR</strong></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have missed a dose of BASAGLAR or if you have not injected enough insulin&nbsp;or are unsure how much you have injected, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p><strong>After injecting</strong></p><p>If you are unsure how much you have injected then check your blood sugar levels before deciding if you need another injection.</p><p><strong>If you stop using BASAGLAR</strong></p><p>This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop BASAGLAR without speaking to a doctor, who will tell you what needs to be done.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice signs of your blood sugar being too low (hypoglycaemia), </strong>take<strong> </strong>the<strong> </strong>action to increase your blood sugar levels <strong>immediately</strong>. Hypoglycaemia (low blood sugar) can be very serious. and is very common with insulin treatment (may affect more than 1 in 10 people). Low blood sugar means that there is not enough sugar in your blood. If your blood sugar level falls too low, you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening.</p><p>For more information, see the box at the end of this leaflet.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Severe allergic reactions </strong></p><p>(rare, may affect up to 1 in 1,000 people) &ndash; the signs may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. Severe<strong> </strong>allergic reactions to insulins may become life-threatening. Tell a doctor straight away if you notice signs of severe allergic reaction.</p><p><strong>Skin changes at the injection site</strong><strong> </strong></p><p>If you inject insulin too often at the same place, the fatty tissue may&nbsp;shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy, may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis, how often they occur is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><ul><li><strong>Skin and allergic reactions at the injection site</strong></li></ul><p>The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation. They can spread around the injection site. Most minor reactions to insulins usually disappear in a few days to a few weeks.</p><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><ul><li><strong>Eye reactions</strong></li></ul><p>A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.</p><ul><li><strong>General disorders</strong></li></ul><p>In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.</p><p><strong>Very rare side-effects </strong>(may affect up to1 in10,000 people)</p><p>In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.</p><p><strong>Use in children and adolescents</strong></p><p>In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.</p><p>Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the label of the pen after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p><u>Not in-use pens</u></p><p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Do not put BASAGLAR next to the freezer compartment or a freezer pack.</p><p>Keep the pre-filled pen in the outer carton in order to protect from light.</p><p><u>In-use pens</u></p><p>Pre-filled pens in use or carried as a spare may be stored for a maximum of 28&nbsp;days below&nbsp;30&deg;C and away from direct heat or direct light. The pen in use must not be stored in the refrigerator. Do not use it after this time period. The pen cap must be put back on the pen after each injection in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is insulin glargine. Each millilitre of the solution contains 100&nbsp;units of the active substance insulin glargine (equivalent to 3.64&nbsp;mg).</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 &ldquo;BASAGLAR&nbsp;contains sodium&rdquo;), hydrochloric acid and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BASAGLAR 100 units/mL solution for injection in a pre-filled pen, KwikPen, is a clear and colourless solution.
BASAGLAR is available in packs containing 5 pre filled pens and in multipacks comprising 2 cartons, each containing 5 pre filled pens.
Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:</p><p>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands</p><p>Manufacturer:</p><p>Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France.</p><p>Eli Lilly Italia S.p.A. Via Gramsci, 731-733. 50019 Sesto Fiorentino, Italy.</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2020
Version 7
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي باسجلار&nbsp; على إنسولين جلارجين، علمًا بأنّ الإنسولين جلارجين هو نوع من أنواع الإنسولين المعدّل، وهو شبيه جدًا بالإنسولين البشري.</p><p dir="RTL">يُستخدم باسجلار لعلاج داء السكري عند البالغين والمراهقين والأطفال ابتداءً من عمر السنتين.</p><p dir="RTL">السكّري هو داء لا ينتج الجسم المصاب به كمية كافية من الإنسولين للسيطرة على مستوى السكر في الدم. للإنسولين جلارجين تأثير ثابت وطويل المفعول في خفض سكّر الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>باسجلار</strong></p><p dir="RTL">إذا كنت تعاني من الحساسية تجاه الإنسولين جلارجين أو أي من المكوّنات الأخرى في هذا الدواء (المذكورة في القسم6).</p><p dir="RTL"><strong>تحذيرات</strong><strong> </strong><strong>واحتياطات</strong></p><p dir="RTL">عليك استشارة طبيبك أو الصيدلي أو ممرضتك قبل استخدام باسجلار.</p><p dir="RTL">يجب اتباع التعليمات بدقة في ما يتعلّق بالجرعات والمراقبة (إجراء اختبارات للدم والبول)، ومتابعة الحمية الغذائية والنشاط البدني (العمل البدني وممارسة التمارين الرياضية)، حسب توجيهات الطبيب المعالج.</p><p dir="RTL">إذا كان مستوى السكّر في دمك منخفضًا جدًا (هبوط سكّر الدم)، عليك اتباع الإرشادات المحددة لحالات هبوط سكّر الدم (المرجو مراجعة المربّع في آخر هذه النشرة).</p><p dir="RTL"><em>تغيرات الجلد في موقع الحقن.</em></p><p dir="RTL">يجب تغيير موقع الحقن لمنع تغيرات الجلد مثل الكتل تحت الجلد. قد لا يعمل الإنسولين بشكل جيد إذا حقنت في منطقة متكتلة (انظر كيفية استخدام باسجلار). اتصل بطبيبك إذا كنت تحقن حالياً في منطقة متكتلة قبل البدء بالحقن في منطقة مختلفة. قد يطلب منك طبيبك التحقق من نسبة السكر في الدم عن كثب،&nbsp; وتعديل جرعة الإنسولين أو الأدوية الأخرى المضادة لمرض السكر.</p><p dir="RTL"><em>السفر</em></p><p dir="RTL">قبل السفر عليك استشارة طبيبك. قد يتوجّب عليكما مناقشة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توفر الإنسولين الخاص بك في البلد الذي تقصده،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمدادات الإنسولين، إلخ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التخزين السليم للإنسولين الخاص بك أثناء السفر،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقيت الوجبات وجرعات الإنسولين أثناء السفر،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار المحتملة المترتبة عن الانتقال إلى مناطق زمنية مختلفة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المخاطر الصحية الجديدة المحتملة في البلدان التي ستسافر إليها،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما عليك القيام به في الحالات الطارئة، عند الشعور بالتوعّك أو المرض.</p><p dir="RTL"><em>الأمراض</em><em> </em><em>والإصابات</em></p><p dir="RTL">في الحالات التالية، قد يتطلّب علاج السكّري لديك الكثير من الرعاية (على سبيل المثال تعديل جرعة الإنسولين، إجراء اختبارات للدم والبول):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال المرض أو الإصابات الخطيرة، قد يرتفع مستوى السكّر في دمك (فرط سكّر الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال عدم تناول ما يكفي من الطعام، قد ينخفض مستوى السكّر في دمك إلى حدّ كبير جدًا (هبوط سكّر الدم).</p><p dir="RTL">في معظم الحالات، ستكون بحاجة إلى طبيب .<strong>احرص</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بطبيب</strong><strong> </strong><strong>في</strong><strong> </strong><strong>وقت</strong><strong> </strong><strong>مبكر</strong><strong>.</strong></p><p dir="RTL">إذا كنت مصابًا بالسكّري من النوع الأول (السكري المعتمد على الإنسولين)، لا تتوقف عن أخذ جرعات الإنسولين واستمرّ بتناول ما يكفي من الكربوهيدرات. كما يجب أن تحرص دومًا على إعلام الأشخاص الذين يعتنون بك أو يعالجونك بأنّك بحاجة إلى الإنسولين.</p><p dir="RTL">يمكن أن يتسبب علاج الإنسولين في إنتاج الجسم أجسامًا مضادة للإنسولين (مواد تعمل ضد الإنسولين)، ومع ذلك، نادرًا ما يتطلب ذلك تغيير جرعة الإنسولين.</p><p dir="RTL">بعض المرضى المصابين بالسكر ي من النوع الثاني منذ فترة طويلة وبمرض في القلب، أو ممّن سبق لهم أن تعرّضوا لسكتة، والذين تمّ علاجهم بواسطة البيوجليتازون والإنسولين، أصيبوا بقصور في القلب .لذا، عليك إبلاغ طبيبك بأسرع وقت ممكن في حال شعرت بأعراض قصور القلب، كضيق في التنفس غير عادي أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).<em>&nbsp;</em></p><p dir="RTL"><em>الخلط بين أنواع</em><em> </em><em>الإنسولين</em></p><p dir="RTL">عليك التحقّق دومًا من العبوة وملصق الإنسولين قبل كلّ حقنة لتفادي استخدام إنسولين آخر غير باسجلار عن طريق الخطأ.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">لا تتوفر أي تجربة لاستخدام الباسجلار لدى الأطفال دون سن السنتين</p><p dir="RTL"><strong>الأدوية</strong><strong> </strong><strong>الأخرى وباسجلار</strong></p><p dir="RTL">تؤثّر بعض الأدوية على مستوى السكّر في الدم )انخفاض أو ارتفاع او كلاهما، بحسب الحالة(، في كلتا الحالتين، قد يتوجّب تعديل جرعة الإنسولين لديك لتفادي أيّ انخفاض أو ارتفاع شديد في مستوى السكّر في الدم. كما يجب توخّي الحذر عند البدء بتناول دواء آخر أو التوقف عنه. عليك إبلاغ طبيبك أو الصيدلي إذا كنت تتناول حالياً &nbsp;أو قد تناولت مؤخرًا أو يحتمل أن تتناول أدوية أخرى .قبل أخذ أيّ دواء، اسأل طبيبك إذا كان من شأنه التأثير على مستوى السكّر في دمك، وإذا كان ثمّة أي إجراءات يجب أن تتخذها.</p><p dir="RTL"><em>&nbsp;</em><em>تشمل الأدوية</em><em> </em><em>التي</em><em> </em><em>قد</em><em> </em><em>تؤدّي</em><em> </em><em>إلى</em><em> </em><em>انخفاض</em><em> </em><em>مستوى</em><em> </em><em>سكّر</em><em> </em><em>ال</em><em>دم </em><em>(</em><em>نقص</em><em> </em><em>سكّر</em><em> </em><em>الدم)</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جميع أدوية السكّري الأخرى،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الأنزيم المحول للأنجيوتنسين (ACE) (المستخدمة لعلاج بعض أمراض القلب أو ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديسوبيراميد (المستخدم لعلاج بعض أمراض القلب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفلوكسيتين (المستخدم لعلاج الإكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفايبرايت (المستخدمة لخفض مستويات الدهون المرتفعة في الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات الأكسيداز الأحادي الأمين (MOA) (المستخدمة لعلاج الإكتئاب)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنتوكسيفيلين، البروبوكسيفين، الساليسيلات (كالأسبيرين، المستخدم لتخفيف الألم وخفض الحمّى)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشابهات السوماتوستاتين (مثل الأوكتريوتيد، المستخدم لعلاج حالة مرضية غير شائعة تتمثّل في ارتفاع إنتاج الجسم لهرمون النمو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية السلفوناميدية.</p><p dir="RTL"><em>تشمل الأدوية</em><em> </em><em>التي</em><em> </em><em>قد</em><em> </em><em>تؤدّي</em><em> </em><em>إلى</em><em> </em><em>ارتفاع</em><em> </em><em>مستوى</em><em> </em><em>سكّر</em><em> </em><em>ال</em><em>دم </em><em>(</em><em>فرط</em><em> </em><em>سكّر</em><em> </em><em>الدم)</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات (مثل&rdquo; الكورتيزون &rdquo;المستخدم لعلاج الإلتهابات)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدانازول (دواء يمنع التبويض)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديازوكسايد (المستخدم لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول (المُستخدمة لعلاج ارتفاع ضغط الدم أو احتباس السوائل المفرط)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلوكاجون (من هرمونات البنكرياس، المُستخدم لعلاج النقص الحاد في سكّر الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإيزونيازيد (المستخدم لعلاج السل)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإستروجينات والبروجستوجين (الموجودة في حبوب منع الحمل المستخدمة لتحديد النسل)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشتقات الفينوثيازين (المستخدمة لعلاج الإضطرابات العصبية النفسية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السوماتروبين (هرمون النمو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المحفزة للجهاز السيمباثاوى (كالإبينيفرين [الأدرينالين] والسالبوتامول والتيربوتالين المستخدمة لعلاج الربو)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمونات الغدة الدرقية (المستخدمة لعلاج اضطرابات الغدة الدرقية)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للذهان غير النمطية (كالكلوزابين والأولانزابين)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات البروتياز (المستخدمة لعلاج فيروس نقص المناعة البشرية).</p><p dir="RTL"><em>قد</em><em> </em><em>يرتفع</em><em> </em><em>مستوى</em><em> </em><em>سكّر</em><em>&nbsp; </em><em>ال</em><em>دم لديك </em><em>&nbsp;</em><em>أو</em><em> </em><em>ينخفض</em><em> </em><em>إذا</em><em> </em><em>كنت</em><em> </em><em>تتناول</em><em>:</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات بيتا (المستخدمة لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكلونيدين (المستخدم لعلاج ارتفاع ضغط الدم)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أملاح الليثيوم (المستخدمة لعلاج الاضطرابات العصبية النفسية).</p><p dir="RTL">يمكن أن يؤدّي عقار البنتاميدين (المستخدم لعلاج بعض العدوى الناجمة عن الطفيليات) إلى هبوط في سكر الدم، قد يعقبه أحيانًا ارتفاع في سكر الدم.</p><p dir="RTL">مثبطات بيتا، كغيرها من الأدوية الداحضة للودي (كالكلونيدين والغوانيثيدين والريزربين)، يمكن أن تُضعف أو حتى أن تقضي تمامًا على الأعراض التحذيرية الأولية التي تساعدك على التعرف على هبوط سكر الدم. إذا لم تكن متأكدًا ما إذا كنت تتناول أيّاً من تلك الأدوية، اسأل طبيبك أو الصيدلي.</p><p dir="RTL"><strong>باسجلار</strong><strong> </strong><strong>والكحول</strong></p><p dir="RTL">قد ترتفع مستويات السكّر في دمك أو تنخفض في حال تناولك للكحول.</p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة الطبيعية</strong></p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي قبل أخذ أيّ دواء.</p><p dir="RTL">أبلغي طبيبك إذا كنت حاملًا أو تخططين للإنجاب، فقد يكون من الضروري تعديل جرعة الإنسولين التي تأخذينها أثناء الحمل وبعد الولادة. كما أنه من المهمّ لصحة الجنين التحكّم الدقيق بالسكّري، بما في ذلك الوقاية من هبوط سكّر الدم.</p><p dir="RTL">إذا كنت ترضعين، استشيري طبيبك لأنّ ذلك قد يستدعي تعديل جرعات الإنسولين ونظامك الغذائي.</p><p dir="RTL"><strong>قيادة</strong><strong> </strong><strong>المركبات</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">قد تنخفض قدرتك على التركيز أو التفاعل إذا كنت تعاني من:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط سكّر الدم (انخفاض مستويات السكّر في دمك)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط سكّر الدم (ارتفاع مستويات السكّر في دمك)،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الإبصار.</p><p dir="RTL">تذكّر هذه المشكلة المحتملة في جميع الحالات التي قد تعرّض فيها نفسك والآخرين للخطر (كقيادة السيّارة أو استخدام الآلات). ينبغي استشارة طبيبك حول القيادة إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من نوبات هبوط سكر الدم بصورة متكرّرة،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو انعدام الأعراض التحذيرية الأولية التي تساعدك على التعرف على حالة هبوط سكّر الدم.</p><p dir="RTL"><strong>باسجلار</strong>&nbsp;<strong>يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقلّ من 1 مليمول (23 ملجم) من الصوديوم في كلّ جرعة، أي أنّ بالإمكان اعتباره &quot;خاليًا من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب استخدام هذا الدواء دائمًا بحسب تعليمات الطبيب .وإذا لم تكن متأكّدًا من طريقة الإستخدام، عليك استشارة الطبيب أو الصيدلي.</p><p dir="RTL">&nbsp;بالرغم من أنّ باسجلار يحتوي على المادة الفعّالة عينها التي يحتوي عليها توجيو (إنسولين جلارجين 300 وحدة/مل)، إلاّ أنّ هذين الدواءين ليسا قابلين للتبديل. فالانتقال من علاج إنسولين إلى آخر يتطلّب وصفة طبيّة وإشرافًا طبيًا ومراقبة جلوكوز الدم. الرجاء استشارة طبيبك للمزيد من المعلومات.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">بناء على نمط حياتك، ونتائج اختبارات سكر الدم لديك )الجلوكوز(، واستخدامك السابق للإنسولين، سيقوم الطبيب بتحديد:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة اليومية من باسجلار التي ستحتاجها ومواعيد أخذها،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوقات فحص مستوى السكر في دمك، وما إذا كنت بحاجة إلى إجراء اختبارات بول،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحالات التي قد تحتاج فيها إلى جرعة أكبر أو أصغر من باسجلار</p><p dir="RTL">باسجلار عبارة عن إنسولين ممتدّ المفعول، وقد يطلب منك الطبيب استخدامه مع إنسولين سريع المفعول أو مع أقراص تستخدم لعلاج ارتفاع مستويات السكر في الدم.</p><p dir="RTL">عوامل عديدة قد تؤثر على مستوى السكر في الدم، ولا بدّ لك من معرفة هذه العوامل لتتمكّن من التعامل بطريقة مناسبة مع التغيرات في مستوى السكر في دمك وتجنّب بلوغها مستويات مرتفعة جدًا أو منخفضة جدًا .لمزيد من المعلومات، يرجى مراجعة المربّع في آخر هذه النشرة.</p><p dir="RTL"><strong>الاستخدام</strong><strong> </strong><strong>لدى</strong><strong> </strong><strong>الأطفال</strong><strong> </strong><strong>والمراهقين</strong></p><p dir="RTL">يمكن للمراهقين والأطفال ابتداءً من عمر السنتين استخدام باسجلار. استخدم هذا الدواء تمامًا كما أخبرك الطبيب.</p><p dir="RTL"><strong>وتيرة</strong><strong> </strong><strong>العلاج</strong></p><p dir="RTL">أنت بحاجة إلى حقنة باسجلار واحدة يوميًا، في الوقت عينه من اليوم.</p><p dir="RTL"><strong>طريقة</strong><strong> </strong><strong>ا</strong>لإ<strong>ستخدام</strong></p><p dir="RTL">باسجلار معدّ للحقن تحت الجلد، ولا يجب حقنه في الوريد، فمن شأن ذلك تغيير مفعوله وقد يؤدي إلى هبوط سكّر الدم.</p><p dir="RTL">سيريك الطبيب منطقة الجلد بجسمك التي يجب أن تحقن فيها باسجلار .وعليك تغيير موقع الوخز لكلّ حقنة ضمن المساحة المحدّدة لذلك.</p><p dir="RTL">يتم حقن باسجلار تحت الجلد&nbsp; في منطقة البطن، الفخذ، الذراع العلوي، المنطقة الدالية أو المنطقة الألوية. يجب دائما تدوير مواقع الحقن داخل المنطقة نفسها من أجل الحد من خطر الحثل الشحمي والداء النشواني الجلدي</p><p dir="RTL"><strong>كيفية</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>باسجلار</strong><strong> </strong><strong>كويك بِن</strong></p><p dir="RTL">باسجلار كويك بِن هو قلم حقن معبّأ مسبقاً، يحتوي على الإنسولين جلارجين ويستخدم مرة واحدة فقط.</p><p dir="RTL"><strong>يرجى</strong><strong> </strong><strong>قراءة </strong><strong>&ldquo;</strong><strong>تعليمات</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>باسجلار&quot;</strong><strong> </strong><strong>المرافقة</strong><strong> </strong><strong>لهذه</strong><strong> </strong><strong>النشرة</strong><strong> </strong><strong>بعناية</strong><strong>.</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>القلم</strong><strong> </strong><strong>تماماً</strong><strong> </strong><strong>بحسب</strong><strong> </strong><strong>تعليمات</strong><strong> </strong><strong>الإستخدام</strong><strong> </strong><strong>هذه</strong><strong>.</strong></p><p dir="RTL">يجب استعمال إبرة جديدة لكل حقنة. استخدم الإبر التي تتوافق مع باسجلار كويك بن فقط (انظر&ldquo; تعليمات استخدام باسجلار&quot;).</p><p dir="RTL">يجب إجراء اختبار السلامة قبل كل عملية حقن.</p><p dir="RTL">عليك معاينة الخرطوشة قبل استخدام قلم الحقن. لا تستخدم باسجلار كويك بن إذا لاحظت أنه يحتوي على جسيمات. لا تستخدمه إلّا إذا كان المحلول شفافًا وعديم اللون يشبه الماء. ولا ترجّ القلم أو تمزجه قبل الاستخدام.<br />للوقاية من احتمال انتقال الأمراض، على كلّ مريض أن يستخدم قلمًا خاصًا به.</p><p dir="RTL">واحرص على عدم تلوّث الإنسولين بالكحول أو أي مطهّرات أو مواد أخرى.</p><p dir="RTL">وعليك استخدام قلم جديد إذا لاحظت أن فعالية التحكم فى مستوى السكّر في دمك تتراجع على نحو مفاجئ .أمّا إذا كنت تعتقد أنّه ثمة مشكلة في قلم باسجلار كويك بن الخاص بك، فعليك استشارة طبيبك أو الصيدلي أو الممرض.</p><p dir="RTL">لا يجب إعادة تعبئة الأقلام الفارغة بل يجب التخلص منها بالطريقة المناسبة.</p><p dir="RTL">لا تستخدم باسجلار كويك بن إذا كان تالفًا أو لا يعمل بشكل صحيح، لا بدّ من التخلص منه واستخدام قلم كويك بن جديد.</p><p dir="RTL">يجب تدوير موقع الحقن باستمرار للحد من خطر الإصابة بالحثل الشحمي والداء النشواني الجلدي. هناك خطر محتمل لتأخير امتصاص الإنسولين وتفاقم السيطرة على نسبة السكر في الدم بعد حقن الإنسولين في المواقع التي تعاني منً هذه التفاعلات. لقد أبلغ على أن التغيير المفاجئ لموقع الحقن في منطقة غير متأثرة يؤدي إلى نقص السكر في الدم. يوصى بمراقبة الجلوكوز في الدم بعد تغيير موقع الحقن، ويمكن النظر في تعديل الجرعة من الأدوية المضادة لمرض السكري.</p><p dir="RTL"><strong>في<strong> </strong>حال</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>جرعة زائدة</strong><strong> </strong><strong>من </strong><strong>باسجلار</strong><strong> </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا</strong><strong> </strong><strong>أخذت</strong><strong> </strong><strong>حقنة</strong><strong> </strong><strong>فيها</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>كبيرة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>محلول<strong> </strong>باسجلار</strong>&nbsp;أو إذا لم تكن متأكدًا من الكميّة التي حقنتها، قد ينخفض مستوى السكّر في دمك إلى حدّ كبير (هبوط سكّر الدم). احرص على التحقّق من مستوى السكّر في دمك بشكل متكرّر. وبصورة عامة، لتفادي نقص سكّر الدم، عليك تناول المزيد من الطعام ومراقبة مستوى السكّر في دمك. لمعلومات حول طريقة معالجة نقص سكّر الدم، يرجى مراجعة المربّع في آخر هذه النشرة.</p><p dir="RTL"><strong>في</strong><strong> </strong><strong>حال</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>باسجلار</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت جرعة من باسجلار أو إذا لم تحقن نفسك بكمية كافية من الإنسولين&nbsp;أو إذا لم تكن متأكدًا من الكميّة التي حقنتها، قد يرتفع مستوى السكّر في دمك إلى مستوى عال جدًا )فرط سكّر الدم). احرص على التحقّق من مستوى السكّر في دمك بشكل متكرّر. لمعلومات حول طريقة معالجة ارتفاع سكّر الدم، يرجى مراجعة المربّع في آخر هذه النشرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>بعد الحقن</strong></p><p dir="RTL">إذا لم تكن متأكدًا من الكميّة التي حقنتها، إفحص مستويات السكر في الدم لديك قبل أن تقرّر ما إذا كنت بحاجة إلى حقنة أخرى.</p><p dir="RTL"><strong>في<strong> </strong>حال</strong><strong> </strong><strong>توقّفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>باسجلار</strong></p><p dir="RTL">قد يؤدّي ذلك إلى فرط حاد في سكّر الدم (زيادة شديدة في مستوى السكّر في الدم) وإلى الحمض الكيتوني (تراكم الأحماض في الدم) لأنّ الجسم يفكّك الدهون بدل السكّر .لا يجب التوقّف عن استخدام باسجلار من دون استشارة الطبيب الذي سيوضح لك ما عليك القيام به.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل &nbsp;طبيبك أو ممرضتك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، من الممكن أن يؤدى هذا الدواء الى آثار جانبية، إلا أنها لا تصيب الجميع.</p><p dir="RTL"><strong>إذا لاحظت وجود علامات تشير إلى انخفاض نسبة السكر في الدم لديك (نقص السكر في الدم)، </strong>فاتخذ الإجراء اللزمة لزيادة مستويات السكر في الدم<strong> على الفور</strong><strong>.</strong> يمكن أن يكون<strong> </strong>هبوط سكّر الدم )انخفاض مستوى السكّر في الدم (خطيرًا جدًا وهو شائع جدًا في علاج الإنسولين (قد يصيب أكثر من شخص من كل 10 أشخاص). انخفاض نسبة السكر في الدم يعني أنه لا يوجد ما يكفي من السكر في دمك .إذا انخفض مستوى السكر في دمك كثيرًا قد تفقد الوعي. كما أنّ نقص<strong> </strong>سكّر الدم الحاد يمكن أن يسبّب تلفًا في الدماغ وقد يكون مميتًا.</p><p dir="RTL">لمزيد من المعلومات، عليك مراجعة المربع في نهاية هذه النشرة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>حساسية</strong><strong> </strong><strong>شديدة</strong><strong> </strong></p><p dir="RTL">نادر، (قد يؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص) قد تشمل الأعراض تفاعلات جلدية واسعة النطاق (طفح جلدي وحكة في جميع أنحاء الجسم)، تورم حاد في الجلد أو الأغشية المخاطية (وذمة وعائية)، ضيق في التنفس، وهبوط في ضغط الدم مع سرعة في ضربات القلب وتعرّق. قد تشكّل أعراض الحساسية الشديدة تجاه الإنسولين وخطرًا على الحياة.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تغيّرات</strong><strong> </strong><strong>الجلد</strong><strong> </strong><strong>في</strong><strong> </strong><strong>موقع</strong><strong> </strong><strong>الحقن</strong></p><p dir="RTL">إذا كنت غالبًا ما تحقن الإنسولين في الموقع عينه من الجلد، فإنّ النسيج الدهني تحت الجلد في هذا الموقع قد ينكمش (ضمور شحمي، قد يصيب شخصا واحدا من بين كل 100 شخص) أو يزداد سماكة (تضخّم شحمي، قد يصيب شخصا واحدا من بين كل 10 أشخاص). قد تتكون أيضا كتل تحت الجلد ناتجة عن تراكم بروتين يسمى الأميلويد (الداء النشواني الجلدي، ومن غير المعروف عدد المرات التي&nbsp; يحدث فيها). قد لا يعطي الإنسولين المحقون التأثير المرجو إذا حقنت في منطقة متكتلة. يجب تغيير موقع الحقن في كلّ مرّة للمساعدة على الوقاية من مثل هذه التغيرات الجلدية.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong> (قد تصيب حتى شخص واحد من بين &nbsp;كل 10 أشخاص)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات الجلد والحساسية في موقع الحقن</strong></p><p dir="RTL">قد تشمل العلامات احمرار، ألم شديد بشكل غير عادي عند الحقن، الحكة، قشعريرة، تورم أو التهاب. يمكن أن تنتشر حول موقع الحقن. عادة ما تختفي معظم ردود الفعل الطفيفة على الإنسولين في غضون بضعة أيام إلى بضعة أسابيع.</p><p dir="RTL"><strong>الآثار الجانبية النادرة</strong> (قد تصيب حتى شخص واحد من بين كل 1000 شخص)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تفاعلات</strong><strong> </strong><strong>العينين</strong></p><p dir="RTL">أيّ تغير ملحوظ (تحسّن أو تدهور) في السيطرة على نسبة السكر في الدم يمكن أن يؤثّر مؤقتًا على الرؤية. إذا كنت مصابًا باعتلال الشبكية التكاثري (مرض في العين مرتبط بمرض السكري)، قد تؤدي حالات الهبوط الحاد في سكر الدم إلى فقدانك للرؤية بشكل مؤقت.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاضطرابات</strong><strong> </strong><strong>العامة</strong></p><p dir="RTL">في بعض الحالات النادرة، قد يؤدّي العلاج بالإنسولين إلى تراكم مؤقت للماء في الجسم، مع تورم في الساقين والكاحلين.</p><p dir="RTL"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>نادرة</strong><strong> </strong><strong>جدًا </strong>(قد تصيب حتى شخص واحد من بين كلّ 10000 شخص)</p><p dir="RTL">في حالات نادرة جدًا، قد يصاب المريض بخلل التذوق (اضطرابات في التذوق) وألم عضليّ (ألم في العضلات).</p><p dir="RTL"><strong>الاستخدام</strong><strong> </strong><strong>لدى</strong><strong> </strong><strong>الأطفال</strong><strong> </strong><strong>والمراهقين</strong></p><p dir="RTL">بصورة عامة، الآثار الجانبية المسجّلة لدى الأطفال والمراهقين حتى عمر 18 سنة مشابهة بتلك التي تصيب البالغين.</p><p dir="RTL">وردت تقارير عن شكاوى حول التفاعلات في موقع الحقن (الألم في موقع الحقن والتفاعل التحسسي) والتفاعلات الجلدية (الطفح والشرى) تسجّل بوتيرة أكبر لدى الأطفال والمراهقين حتى عمر 18 سنة، منه لدى البالغين.</p><p dir="RTL"><strong>الإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، عليك استشارة طبيبك أو الصيدلي، وهذا يشمل أيّ آثار جانبية محتملة لم ترد في هذه النشرة .كما أنّ بإمكانك الإبلاغ عن الآثار الجانبية مباشرة من خلال نظام الإبلاغ الوطني المذكور في القسم 6. إن الإبلاغ عن الآثار الجانبية يساعد في توفير معلومات إضافية حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الاحتفاظ بهذا الدواء بعيدًا عن رؤية الأطفال ومتناولهم.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انقضاء تاريخ صلاحيته المبيّن على العلبة وعلى ملصق الخرطوشة بعد رمز&ldquo;EXP&rdquo; ، علمًا بأنّ تاريخ انتهاء الصلاحية يشير إلى آخر يوم من الشهر المذكور.</p><p dir="RTL"><u>الأقلام</u><u> </u><u>غير</u><u> </u><u>المفتوحة</u></p><p dir="RTL">يجب تخزينها في الثلاجة) بين 2 و 8 درجات مئوية). لا يجب تجميدها.</p><p dir="RTL">لا يجب وضع خراطيش باسجلار بالقرب من المجمد أو من علبة تجميد.</p><p dir="RTL">يجب إبقاء الأقلام في العلبة الخارجية لحمايتها من الضوء.</p><p dir="RTL"><u>الأقلام</u><u> </u><u>قيد</u><u> </u><u>الاستخدام</u></p><p dir="RTL">يمكن تخزين الأقلام المعبأة مسبقاً التي قيد الاستخدام أو التي يحملها المريض معه كاحتياطي، لمدة 28 يومًا كحدّ أقصى، على حرارة ما دون &nbsp;30درجة مئوية، بعيدًا عن الضوء أو الحرارة المباشرة .لا يجب تخزين القلم قيد الإستخدام في الثلاجة، ولا يجب استخدامه بعد انقضاء الفترة المحددة .يجب إعادة وضع الغطاء بعد كل عملية حقن لحمايته من الضوء.</p><p dir="RTL">لا يجب رمي أيّ أدوية في مياه الصرف الصحي أو مع النفايات المنزلية .اسأل الصيدلي حول كيفية التخلّص من الأدوية التي توقّفت عن استخدامها .من شأن هذه التدابير المساهمة في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي الإنسولين جلارجين .يحتوي كلّ مليلتر من المحلول على100 &nbsp;وحدة من هذه المادة الفعالة (ما يعادل 3.64 ملجم).</p><p dir="RTL">&nbsp;- المكوّنات الأخرى هي :أكسيد الزنك، الميتاكريزول، الجليسيرول، هيدروكسيد الصوديوم (المرجو مراجعة القسم 2 &quot;&nbsp;باسجلار&nbsp;يحتوي على الصوديوم&quot;)، حمض الهيدروكلوريك، والماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">باسجلار 100 وحدة/مل، محلول شفّاف وعديم اللون، معدّ للحقن في قلم كويك بن معبأ مسبقاً.</p><p dir="RTL">إن الباسجلار متوفر في علب تضمّ 5 أقلام، أو في علبة مزدوجة تضمّ &nbsp;علبتين، وفي كل علبة 5 أقلام معبأة مسبقاً.</p><p dir="RTL">قد لا تكون جميع أحجام العلب متوافرة في السوق المحلي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل رخصة التسويق:</p><p dir="RTL">إيلي ليلي هولندا، بابندوربسوغ 83، 3528، BJ أوترخت، هولندا.</p><p dir="RTL">المصنّع:</p><p dir="RTL">إيلي ليلي فرنسا، شارع الكولونيل ليلي، F-67640 فغرشايم، فرنسا</p><p dir="RTL">إيلي ليلي إيطاليا &nbsp;S.p.A.عبر جرامشي 50019 .731-733 سيستو فيورنتينو، إيطاليا.</p><p dir="RTL">للحصول على معلومات عن هذا الدواء، يُرجى الاتصال بالشركة صاحبة تفويض التسويق المحلي:</p><p dir="RTL">شركة إيلي ليلي آند كومباني &ndash; المملكة العربية السعودية</p><p dir="RTL">ص.ب: 92120</p><p dir="RTL">الطابق 16، مبنى رقم 3074،</p><p dir="RTL">برج ب، أبراج العُليَّا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العُليَّا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر: 966114617800+، 966114617850+</p><p dir="RTL">الفاكس: 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2020
النسخة ٧


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BASAGLAR 100 units/mL KwikPen solution for injection in a pre-filled pen
BASAGLAR 100 units/mL Tempo Pen solution for injection in a pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL contains 100 units insulin glargine* (equivalent to 3.64 mg). 

Each pen contains 3 mL of solution for injection, equivalent to 300 units. 

* produced by recombinant DNA technology in Escherichia coli. 

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

Clear, colourless solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of diabetes mellitus in adults, adolescents and children aged 2&nbsp;years and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>BASAGLAR contains insulin glargine, an insulin analogue and has a prolonged duration of action.</p><p>BASAGLAR should be administered once daily at any time but at the same time each day.</p><p>The BASAGLAR dose regimen (dose and timing) should be individually adjusted. In patients with type&nbsp;2 diabetes mellitus, BASAGLAR can also be given together with orally active antidiabetic medicinal products.</p><p>The potency of this medicinal product is stated in units. These units are exclusive to insulin glargine and are not the same as IU or the units used to express the potency of other insulin analogues (see section 5.1).</p><p><u><em>Special populations</em></u></p><p><em>Elderly population (&ge;65 years old)</em></p><p>In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.</p><p><em>Renal impairment</em></p><p>In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.</p><p><em>Hepatic impairment</em></p><p>In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.</p><p><u><em>Paediatric population</em></u></p><p><em>Adolescents and children aged 2 years and older</em></p><p>The safety and efficacy of insulin glargine have been established in adolescents and children aged 2&nbsp;years and older (see section 5.1). The dose regimen (dose and timing) should be individually adjusted.</p><p><em>Children below 2 years of age</em></p><p>The safety and efficacy of insulin glargine have not been established. No data are available.</p><p><u><em>Switch from other insulins to BASAGLAR</em></u></p><p>When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with BASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast-acting insulin analogues or the dose of oral antidiabetic medicinal products).</p><p><u><em>Switch from twice daily NPH insulin to BASAGLAR</em></u></p><p>To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with BASAGLAR should reduce their daily dose of basal insulin by 20-30&nbsp;% during the first weeks of treatment.</p><p><u><em>Switch from insulin glargine 300 units/ml to BASAGLAR</em></u></p><p>BASAGLAR and Toujeo (insulin glargine 300 units/ml) are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with BASAGLAR should reduce their dose by approximately 20%.</p><p>During the first weeks the reduction should, at least partially, be compensated by an increase in mealtime insulin, after this period the regimen should be adjusted individually.</p><p>Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.</p><p>With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary. Dose adjustment may also be required, for example, if the patient&#39;s weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4).</p><p>Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with BASAGLAR.</p><p><u>Method of administration</u></p><p>BASAGLAR is administered subcutaneously.</p><p>BASAGLAR should not be administered intravenously. The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue. Intravenous administration of the usual subcutaneous dose could result in severe hypoglycaemia.</p><p>There are no clinically relevant differences in serum insulin or glucose levels after abdominal, deltoid or thigh administration of insulin glargine. Injection sites should always be rotated within the same region in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and 4.8).</p><p>BASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</p><p>For further details on handling, see section 6.6.</p><p>Before using BASAGLAR solution for injection in pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).</p><p><em><u>KwikPen</u></em></p><p>The KwikPen is registered in two presentations. One delivers 1&nbsp;&ndash;60&nbsp;units in steps of 1&nbsp;unit in a single injection and the other delivers 1&nbsp;&ndash;&nbsp;80&nbsp;units in steps of 1&nbsp;unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen.</p><p><em><u>Tempo Pen</u></em></p><p>The Tempo Pen delivers 1&nbsp;&ndash;&nbsp;80&nbsp;units in steps of 1&nbsp;unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen.</p><p>The Tempo Pen can be used with the optional transfer module Tempo Smart Button (see section 6.6).</p><p>As with any insulin injection, when using the Tempo Pen, Smart Button and the mobile application, the patient should be instructed to check their blood sugar levels when considering or making decisions about another injection if they are unsure how much they have injected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered medicinal product should be clearly recorded.</p><p><u>Diabetic ketoacidosis</u></p><p>BASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously is recommended in such cases.</p><p><u>Insulin requirements and dose adjustments</u></p><p>In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient&#39;s adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.</p><p>Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer), type (regular, NPH, lente, long‑acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for a change in dose.</p><p><u>Hypoglycaemia</u></p><p>The time of occurrence of hypoglycaemia depends on the action profile of the insulins used and may, therefore, change when the treatment regimen is changed. Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.</p><p>Particular caution should be exercised, and intensified blood glucose monitoring is advisable in patients in whom hypoglycaemic episodes might be of particular clinical relevance, such as in patients with significant stenoses of the coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral complications of hypoglycaemia) as well as in patients with proliferative retinopathy, particularly if not treated with photocoagulation (risk of transient amaurosis following hypoglycaemia).</p><p>Patients should be aware of circumstances where warning symptoms of hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be changed, be less pronounced or be absent in certain risk groups. These include patients:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in whom glycaemic control is markedly improved,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in whom hypoglycaemia develops gradually,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who are elderly,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after transfer from animal insulin to human insulin,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in whom an autonomic neuropathy is present,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with a long history of diabetes,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suffering from a psychiatric illness,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; receiving concurrent treatment with certain other medicinal products (see section 4.5).</p><p>Such situations may result in severe hypoglycaemia (and possibly loss of consciousness) prior to the patient&#39;s awareness of hypoglycaemia.</p><p>The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.</p><p>If normal or decreased values for glycated haemoglobin are noted, the possibility of recurrent, unrecognised (especially nocturnal) episodes of hypoglycaemia must be considered.</p><p>Adherence of the patient to the dose and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia. Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment. These include:</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the injection area,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; improved insulin sensitivity (e.g., by removal of stress factors),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unaccustomed, increased or prolonged physical activity,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; intercurrent illness (e.g. vomiting, diarrhoea),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inadequate food intake,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; missed meals,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol consumption,</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or adrenocortical insufficiency),</p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concomitant treatment with certain other medicinal products.</p><p><u>Injection technique</u></p><p>Patients must be instructed to perform continuous rotation of the injection site to reduce the risk of developing lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin absorption and worsened glycaemic control following insulin injections at sites with these reactions. A sudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. Blood glucose monitoring is recommended after the change in the injection site, and dose adjustment of antidiabetic medications may be considered.</p><p><u>Intercurrent illness</u></p><p>Intercurrent illness requires intensified metabolic monitoring. In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type&nbsp;1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food, or are vomiting etc. and they must never omit insulin entirely.</p><p><u>Insulin antibodies</u></p><p>Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).</p><p><u>Medication errors</u></p><p>Medication errors have been reported in which other insulins, particularly short‑acting insulins, have been accidentally administered instead of insulin glargine. Insulin label must always be checked before each injection to avoid medication errors between BASAGLAR pre-filled pen as well as other insulins.</p><p><u>Combination of BASAGLAR with pioglitazone</u></p><p>Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. This should be kept in mind if treatment with the combination of pioglitazone and BASAGLAR is considered. If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs.</p><p><u>Tempo Pen</u></p><p>The Tempo Pen contains a magnet (see section 6.5) that may interfere with the functions of an implantable electronic medical device, such as a pacemaker. The magnetic field extends to approximately 1.5&nbsp;cm.</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, i.e., essentially &ldquo;sodium‑free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.</p><p>Substances that may enhance the blood-glucose‑lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide antibiotics.</p><p>Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors.</p><p>Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.</p><p>In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1,000&nbsp;pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine.</p><p>Animal data do not indicate reproductive toxicity.</p><p>The use of BASAGLAR may be considered during pregnancy, if clinically needed.</p><p>It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy to prevent adverse outcomes associated with hyperglycaemia. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose control is essential.</p><p><u>Breast-feeding</u></p><p>It is unknown whether insulin glargine is excreted in human milk. No metabolic effects of ingested insulin glargine on the breastfed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract.</p><p>Breast-feeding women may require adjustments in insulin dose and diet.</p><p><u>Fertility</u></p><p>Animal studies do not indicate direct harmful effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient&#39;s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using&nbsp;machines).</p><p>Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machines in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>Hypoglycaemia, (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).</p><p><u>Tabulated list of adverse reactions</u></p><p>The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: &ge;1/10; common: &ge;1/100 to &lt;1/10; uncommon: &ge;1/1,000 to &lt;1/100; rare: &ge;1/10,000 to &lt;1/1,000; very rare: &lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:974px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>MedDRA system organ classes</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top; width:77px"><p><strong>Very rare</strong></p></td><td style="text-align:center; vertical-align:middle; width:88px"><strong>Not known</strong></td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Immune system disorders </strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Allergic reactions</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypoglycaemia</p></td><td colspan="2" style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dysgeusia</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>X</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Eyes disorders</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Visual impairment</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Retinopathy</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lipohypertrophy</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lipoatrophy</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top">&nbsp; &nbsp;Cutaneous amyloidosis</td><td colspan="2" style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:77px">&nbsp;</td><td style="vertical-align:top; width:88px">&nbsp; &nbsp;X</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p>Myalgia</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>X</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td colspan="8" style="vertical-align:top; width:882px"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injection site reactions</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>X</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td><td style="vertical-align:top; width:77px"><p>&nbsp;</p></td><td style="vertical-align:top; width:88px">&nbsp;</td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><u><em>Metabolism and nutrition disorders</em></u></p><p>Severe hypoglycaemic attacks, especially if recurrent, may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may be life-threatening. In many patients, the signs and symptoms of neuroglycopenia are preceded by signs of adrenergic counter-regulation. Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms.</p><p><u><em>Immune system disorders</em></u></p><p>Immediate-type allergic reactions to insulin are rare. Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening.</p><p><u><em>Eyes disorders</em></u></p><p>A marked change in glycaemic control may cause temporary visual impairment, due to temporary alteration in the turgidity and refractive index of the lens.</p><p>Long-term improved glycaemic control decreases the risk of progression of diabetic retinopathy. However, intensification of insulin therapy with abrupt improvement in glycaemic control may be associated with temporary worsening of diabetic retinopathy. In patients with proliferative retinopathy, particularly if not treated with photocoagulation, severe hypoglycaemic episodes may result in transient amaurosis.</p><p><u><em>Skin and subcutaneous tissue disorders</em></u></p><p>Lipodystrophy and cutaneous amyloidosis may occur at the injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions (see section 4.4).</p><p><u><em>General disorders and administration site conditions</em></u></p><p>Injection site reactions include redness, pain, itching, hives, swelling, or inflammation. Most minor reactions to insulins at the injection site usually resolve in a few days to a few weeks.</p><p>Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.</p><p><u><em>Paediatric population</em></u></p><p>In general, the safety profile for children and adolescents (&le;&nbsp;18&nbsp;years of age) is similar to the safety profile for adults. The adverse reaction reports received from post marketing surveillance included relatively more frequent injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) in children and adolescents (&le;&nbsp;18&nbsp;years of age) than in adults. Clinical study safety data are not available for children under 2&nbsp;years.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system below.</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>.&nbsp; &nbsp; &nbsp; &nbsp;SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Insulin overdose may lead to severe and sometimes long-term and life-threatening hypoglycaemia.</p><p><u>Management</u></p><p>Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or physical activity may be needed.</p><p>More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycaemia may recur after apparent clinical recovery.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, insulins and analogues for injection, long-acting. ATC Code: A10AE04.</p><p>BASAGLAR is a biosimilar medicinal product. Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.</p><p><u>Mechanism of action</u></p><p>Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. It is completely soluble at the acidic pH of the BASAGLAR injection solution (pH&nbsp;4). After injection into the subcutaneous tissue, the acidic solution is neutralised leading to formation of micro-precipitates from which small amounts of insulin glargine are continuously released, providing a smooth, peakless, predictable concentration/time profile with a prolonged duration of action.</p><p>Insulin glargine is metabolised into 2 active metabolites M1 and M2 (see section 5.2).</p><p><u><em>Insulin receptor binding</em></u></p><p><em>In vitro</em> studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.</p><p>IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin.</p><p>The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type&nbsp;1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate the mitogenic-proliferative pathway; however, the therapeutic concentrations found in insulin therapy, including in BASAGLAR therapy, are considerably lower than the pharmacological concentrations required to activate the IGF-1 pathway.</p><p><u>Pharmacodynamic effects</u></p><p>The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.</p><p>In clinical pharmacology studies, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses. As with all insulins, the time course of action of insulin glargine may be affected by physical activity and other variables.</p><p>In euglycaemic clamp studies in healthy subjects or in patients with type&nbsp;1 diabetes, the onset of action of subcutaneous insulin glargine was slower than with human NPH insulin, its effect profile was smooth and peakless, and the duration of its effect was prolonged.</p><p>The following graph shows the results from a study in patients:</p><p><strong>Figure 1: </strong><strong>Activity profile in patients with type</strong>&nbsp;<strong>1 diabetes</strong></p><p><img alt="" width="537" height="287" src="data:image/jpeg;base64,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" />&nbsp;</p><p>Determined as amount of glucose infused to maintain constant plasma glucose levels (hourly mean values)</p><p>The longer duration of action of subcutaneous insulin glargine is directly related to its slower rate of absorption and supports once daily administration. The time course of action of insulin and insulin analogues such as insulin glargine may vary considerably in different individuals or within the same individual</p><p>In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type&nbsp;1 diabetes.</p><p><u>Clinical safety and efficacy</u></p><p>In clinical studies, antibodies that cross-react with human insulin and insulin glargine were observed with the same frequency in both NPH-insulin and insulin glargine treatment groups.</p><p>Effects of insulin glargine (once daily) on diabetic retinopathy were evaluated in an open-label 5&nbsp;year NPH-controlled study (NPH given bid) in 1024 type&nbsp;2 diabetic patients in which progression of retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by fundus photography. No significant difference was seen in the progression of diabetic retinopathy when insulin glargine was compared to NPH insulin.</p><p>The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type&nbsp;2 diabetes mellitus treated with &le;1 antidiabetic oral agent (88% of participants). Participants were randomised (1:1) to receive insulin glargine (n=6264), titrated to reach FPG &le;95 mg/dL (5.3 mM), or standard care (n=6273).</p><p>The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.</p><p>Secondary endpoints included all-cause mortality and a composite microvascular outcome.</p><p>Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome.</p><p>Mean dose of insulin glargine by study end was 0.42 U/kg. At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. Over the course of this 6-year study, 42% of the insulin glargine group did not experience any hypoglycaemia.</p><p>At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group.</p><p><u>Paediatric population</u></p><p>In a randomised, controlled clinical study, paediatric patients (age range 6 to 15&nbsp;years) with type&nbsp;1 diabetes (n=349) were treated for 28&nbsp;weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily. Similar effects on glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed in both treatment groups, however fasting plasma glucose decreased more from baseline in the insulin glargine group than in the NPH group. There was less severe hypoglycaemia in the insulin glargine group as well. One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2&nbsp;years. No new safety signals were seen during this extended treatment with insulin glargine.</p><p>A crossover study comparing insulin glargine plus lispro insulin to NPH plus regular human insulin (each treatment administered for 16 weeks in random order) in 26 adolescent type&nbsp;1 diabetic patients aged 12 to 18&nbsp;years was also performed. As in the paediatric study described above, fasting plasma glucose reduction from baseline was greater in the insulin glargine group than in the NPH group. HbA<sub>1c</sub> changes from baseline were similar between treatment groups; however blood glucose values recorded overnight were significantly higher in the insulin glargine/ lispro group than the NPH/regular group, with a mean nadir of 5.4&nbsp;mM vs. 4.1&nbsp;mM. Correspondingly, the incidences of nocturnal hypoglycaemia were 32&nbsp;% in the insulin glargine / lispro group vs. 52&nbsp;% in the NPH / regular group.</p><p>A 24-week parallel group study was conducted in 125 children with type&nbsp;1 diabetes mellitus aged 2 to 6&nbsp; years, comparing insulin glargine given once daily in the morning to NPH insulin given once or twice daily as basal insulin. Both groups received bolus insulin before meals. The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycaemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin and glucose variabilities were comparable in both treatment groups. No new safety signals were observed in this trial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</strong></p><p><u>Absorption</u></p><p>In healthy subjects and diabetic patients, insulin serum concentrations indicated a slower and much more prolonged absorption and showed a lack of a peak after subcutaneous injection of insulin glargine in comparison to human NPH insulin. Concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin.</p><p>Insulin glargine injected once daily will reach steady state levels in 2-4 days after the first dose.</p><p><u>Biotransformation</u></p><p>After subcutaneous injection in diabetic patients, insulin glargine is rapidly metabolised at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is the metabolite M1. The exposure to M1 increases with the administered dose of insulin glargine.</p><p>The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.</p><p><u>Elimination</u></p><p>When given intravenously the elimination half-life of insulin glargine and human insulin were comparable.</p><p><u>Special populations</u></p><p>In clinical studies, subgroup analyses based on age and gender did not indicate any difference in safety and efficacy in insulin glargine-treated patients compared to the entire study population.</p><p><u><em>Paediatric population</em></u></p><p>Pharmacokinetics in children aged 2 to less than 6 years with type&nbsp;1 diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zinc oxide.&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;q.s. to provide Zn2+ content of 0.03 mg/mL</p><p>Metacresol&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.2.7 mg/mL</p><p>Glycerol&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;...17 mg/mL</p><p>Hydrochloric acid&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;...for pH adjustment</p><p>Sodium hydroxide&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..for pH adjustment</p><p>Water for injections&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..q.s. to 1 mL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
Shelf life after first use 
The medicinal product may be stored for a maximum of 28 days below 30°C and away from direct heat or direct light. Pens in use must not be stored in the refrigerator. 
The pen cap must be put back on the pen after each injection in order to protect from light

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Before use</u></p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>Do not freeze.</p><p>Do not store BASAGLAR next to the freezer compartment or a freezer pack.</p><p>Keep the pre-filled pen in the outer carton in order to protect from light.</p><p><u>In use </u></p><p>For storage conditions after first opening of this medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>KwikPen</u></p><p>3 mL solution in a cartridge (type&nbsp;1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal.</p><p>The cartridge is sealed in a disposable pen injector.</p><p>Packs of 5 pre-filled pens and multipacks containing 10 (2 packs of 5) pre-filled pens.</p><p><u>Tempo Pen</u></p><p>3 mL solution in a cartridge (type&nbsp;1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable pen injector. The Tempo Pen contains a magnet (see section&nbsp;4.4).</p><p>Packs of 5&nbsp;pre-filled pens and multipacks containing 10 (2 packs of 5) pre-filled pens.</p><p>Not all pack sizes may be marketed.</p><p>Needles are not included in the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BASAGLAR must not be mixed with any other insulin or medicinal products or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</p><p>Inspect the cartridge before use. It must only be used if the solution is clear, colourless, with no solid particles visible, and if it is of water-like consistency. Since BASAGLAR is a solution, it does not require re-suspension before use.</p><p>BASAGLAR must not be mixed with any other insulin or diluted. Mixing or diluting can change its time/action profile and mixing can cause precipitation.</p><p>Empty pens must never be reused and must be properly discarded.</p><p>To prevent the possible transmission of disease, each pen must be used by one patient only.</p><p>Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins (see section 4.4).</p><p>The patient should be advised to read the instructions for use included in the package leaflet carefully before using BASAGLAR solution for injection in pre-filled pen.</p><p><u>Tempo Pen</u></p><p>The Tempo Pen is designed to work with the Tempo Smart Button. The Tempo Smart Button is an optional product that can be attached to the Tempo Pen dose knob and aids in transmitting Basaglar dose information from the Tempo Pen to a compatible mobile application. The Tempo Pen injects insulin with or without the Tempo Smart Button attached. To transmit data to the mobile application, follow the instructions provided with the Tempo Smart Button and the instructions with the mobile application.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                23 July 2020
Version 8


            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>